Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Human Growth Hormone Drugs Market 2015-2022 - Global Strategic Business Report 2017: Pediatric GHD Rules, While Adult GHD Remains Underserved - Research and Markets


News provided by

Research and Markets

07 Mar, 2017, 14:30 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Mar 07, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Human Growth Hormone Drugs - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million.

The report profiles 28 companies including many key and niche players such as

  • Eli Lilly and Company (US)
  • Ferring Holding SA (Switzerland)
  • Genentech, Inc. (US)
  • GeneScience Pharmaceuticals Co., Ltd. (China)
  • Merck KgaA (Germany)
  • Novo Nordisk A/S (Denmark)
  • Pfizer, Inc. (US)
  • Sandoz International GmbH (Germany)

Key Topics Covered:

1. INDUSTRY OVERVIEW

  • Market Outlook
  • Evolution of Recombinant Human Growth Hormones (hGH)
  • List of Select Approved Prescription Daily-dose hGH Products by Indication
  • Patent Expiry Paves Way for the Emergence of Biosimilars; Impact Remains Small
  • Strong Innovation Drive Takes Hold of the hGH Industry
  • Sizing the Market
  • Key Growth Drivers
  • High Prevalence of Growth Hormone Deficiency Disorders
  • Innovations Hold the Key to Market Growth
  • New Indications for hGH Replacement Therapy
  • Major Growth Restraining Factors
  • Complex Delivery System
  • High Cost of hGH Treatment
  • Difficulty in Securing Reimbursement
  • Biosimilars Threaten Revenue Growth Erosion
  • Limited Pharmacological Differences Exist Among Current Agents

2. MARKET TRENDS & ISSUES

  • Pediatric GHD Rules, while Adult GHD Remains Underserved
  • Long-Acting hGH Drugs
  • a Potential Game Changer
  • Select Long-Acting hGH Products in Pipeline by Development Stage
  • Biosimilars Create Little Impact, Further Validation to Expand Indications and Growth
  • Manufacturers Bet on Novel Drug Delivery Technologies
  • Phase IV Studies Necessitated for First Biosimilars
  • Needle-less Drug Delivery Systems to Wipe Out of Syringes
  • Drug Delivery Device Options for Marketed hGH Products
  • Growing Non-Prescription/Off-Label Usage
  • A Potential Health Hazard
  • Oral hGH Secretagogues
  • An Alternative to Controversial hGH Injections in Professional Sports
  • Risk of Cancer Necessitates Judicious Use of hGH in Children
  • Dose Titration
  • A Key to Achieve Enhanced Tolerability
  • Growth Concerns about Prolonged Usage of Growth Hormones

3. COMPETITIVE LANDSCAPE

  • hGH
  • A Highly Consolidated Market
  • Overview of Select Leading Marketed hGH Products
  • Norditropin
  • Genotropin
  • Humatrope
  • Saizen
  • Omnitrope
  • the Somatropin Biosimilar
  • Somatropin Biopartners
  • Review of Select hGH Products in Pipeline
  • OPKO's Lagova to be the Earliest of Long-Acting hGHs to Hit the Market
  • Somavaratan Advances Further in Clinical Trials
  • Somapacitan Moves Ahead in Development; Nears Commercial Launch
  • TransCon hGH
  • the Potential Blockbuster hGH Product in Waiting
  • HanAll's Vitatropin

4. HUMAN GROWTH HORMONE: AN OVERVIEW

  • Key Factors Controlling Natural hGH Secretion
  • Structure of hGH
  • Functions Performed by hGH in the Human Body
  • Benefits of Adequate hGH
  • Effects of Human Growth Hormone Imbalances
  • Hypopituitarism
  • Evolution of Growth Hormone Replacement Therapy
  • Indications for Exogenous hGH Administration
  • Growth Hormone Deficiency (GHD)
  • Symptoms of Adult Growth Hormone Deficiency
  • Idiopathic Short Stature
  • Noonan Syndrome
  • Prader-Willi Syndrome
  • Turner Syndrome
  • Short Stature Homeobox Gene
  • Small for Gestational Age
  • Chronic Renal Insufficiency
  • Short Bowel Syndrome
  • Other Medical Conditions
  • Off-label Applications
  • Contraindications for Somatropin Therapy
  • Safety Review of hGH Therapy
  • Reported Adverse Effects of Inaccurate rhGH Dosages
  • Risks Involved with Pediatric/Adolescent hGH Replacement Therapy
  • Risks Involved with Adult hGH Replacement Therapy

5. RECENT INDUSTRY ACTIVITY

  • NHI Includes JCR Pharmaceuticals's GROWJECT Liquid hGH Formulations in Reimbursement Listing
  • Ascendis Pharma Commences Phase III Trial on TransCon hGH
  • Teijin Inks License Deal with Versartis for Somavaratan
  • JCR Pharmaceuticals Obtains Japanese MHLW Approval for Growject® Liquid Formulations
  • Merck Dissolves Merck Serono and Merck Millipore Brands, Relaunches Merck Brand
  • EMD Serono and Aeterna Zentaris Finalize Promotional Services Deal for Saizen
  • Versartis Commences Phase II/III Studies for VRS-317 in Japan
  • Ferring Pharmaceuticals Obtains FDA Clearance for Name Change of Growth Hormone
  • Hanmi Introduces Development-Stage Long Acting hGH
  • Novo Nordisk Obtains FDA Approval for Norditropin® FlexPro® Prefilled Pen
  • OPKO and Pfizer Ink Agreement for Development of OPKO's Long- acting hGH-CTP
  • Pfizer Announces Positive Results from Phase 3B Study on Genotropin for SGA in Children

6. FOCUS ON SELECT GLOBAL PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 28 (including Divisions/Subsidiaries 33)

- The United States (10)
- Canada (1)
- Japan (2)
- Europe (10)
- Germany (4)
- The United Kingdom (2)
- Rest of Europe (4)
- Asia-Pacific (Excluding Japan) (9)
- Middle East (1)

For more information about this report visit http://www.researchandmarkets.com/research/73dp74/human_growth

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.